エピソード

  • China's 2025 MedTech Surge: NMPA's New Fast-Track for Innovative Devices

    China's 2025 MedTech Surge: NMPA's New Fast-Track for Innovative Devices
    2025/06/03
    This episode delves into China's transformative 2025 NMPA Roadmap, detailing how the "NMPA regulation 2025" aims to accelerate approvals for innovative medical devices. We explore the new Special Review Pathway, shortened clinical trial timelines, priority review categories, and expanded domestic production opportunities, offering insights for manufacturers navigating this evolving regulatory landscape. Key Questions: • What are the headline changes in China's NMPA 2025 roadmap for medical devices? • How does the "NMPA regulation 2025" plan to speed up innovative device approvals by 2027? • What criteria must a device meet to qualify for the NMPA's Special Review Pathway introduced in April 2025? • Are clinical trial approval times for medical devices in China being reduced? • Which medical devices, such as those for rare diseases or AI-diagnostics, will get priority NMPA review? • How will the new rules impact foreign manufacturers producing innovative devices in China? • What can we expect from the Medical Devices Administration Law anticipated in late 2025? • How is China aiming for greater transparency and alignment with global regulatory standards? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    5 分
  • Saudi MedTech Breakthrough: Understanding the SFDA's MDS-G002 Pathway

    Saudi MedTech Breakthrough: Understanding the SFDA's MDS-G002 Pathway
    2025/06/02
    This episode delves into the Saudi Food and Drug Authority’s (SFDA) Innovative Medical Devices Pathway (MDS-G002), a strategic initiative designed to significantly accelerate market entry for novel medical technologies in Saudi Arabia. We explore the key features, eligibility criteria, and the profound impact this pathway has on reducing time-to-market in the Gulf region, fostering local manufacturing under Saudi Vision 2030, and positioning the Kingdom as a MedTech innovation hub. Key Questions: • What is the SFDA's Innovative Medical Device Pathway (MDS-G002)? • How does MDS-G002 accelerate regulatory review for new medical devices? • What are the dual approval mechanisms offered under this pathway? • Who is eligible for conditional marketing authorization in Saudi Arabia? • How does this pathway support Saudi Arabia's Vision 2030 and local manufacturing? • What makes a medical device "innovative" according to SFDA criteria? • How does faster SFDA approval impact device availability in the wider Gulf region? • What kind of support does SFDA offer to innovators utilizing this pathway? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    4 分
  • Brazil's RDC 751/2022: Your 2025 MedTech Compliance Guide

    Brazil's RDC 751/2022: Your 2025 MedTech Compliance Guide
    2025/06/01
    This episode unpacks Brazil's transformative RDC 751/2022 medical device regulation, effective since March 1, 2023. We cover the updated four-tier risk classification system, the 22 detailed classification rules (including those for SaMD and nanomaterials) aligning with EU MDR, and the distinct Notification (Class I/II) versus Registration (Class III/IV) pathways. Exporters will receive essential compliance tips for 2025, focusing on re-classification, technical documentation, labeling in Brazilian Portuguese, B-GMP, and e-labeling provisions to successfully navigate the Brazilian market. Key Questions: • What are the four risk classes under Brazil's RDC 751/2022? • How do the 22 new classification rules impact your medical device? • What are the key differences between Notification and Registration pathways in Brazil? • Have you updated your device classification and documentation since March 1, 2023? • What are the specific requirements for SaMD and nanomaterials under the new Brazilian rules? • What are the crucial labeling and IFU changes, including language requirements? • Is your B-GMP certification compliant for Brazilian market access? • How can you leverage e-labeling options under RDC 751/2022? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    3 分
  • FDA's Landmark QMSR Rule: ISO 13485 Harmonization for 2026

    FDA's Landmark QMSR Rule: ISO 13485 Harmonization for 2026
    2025/05/31
    This episode delves into the U.S. FDA's significant 2024 Quality Management System Regulation (QMSR) final rule. We explore how this rule, effective February 2, 2026, aligns 21 CFR Part 820 with the international standard ISO 13485:2016, discuss key changes, FDA-specific additions, and the crucial steps medical device manufacturers must take to prepare for this transition. Key Questions: • What is the FDA's new Quality Management System Regulation (QMSR) issued on January 31, 2024? • How does the QMSR integrate ISO 13485:2016 into U.S. medical device regulations? • When is the critical effective date for the new QMSR requirements? • What are the main differences between the outgoing Quality System Regulation (QSR) and the incoming QMSR? • Beyond ISO 13485, what supplemental FDA-specific requirements must manufacturers address? • How will FDA inspections adapt to the new QMSR framework? • What actions should manufacturers prioritize during the two-year transition period ending February 2, 2026? • Is achieving ISO 13485 certification sufficient for QMSR compliance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    4 分
  • EU MDR's New Timetable: Are You Ready for 2025, 2027, and 2028?

    EU MDR's New Timetable: Are You Ready for 2025, 2027, and 2028?
    2025/05/30
    This episode delves into the crucial extended transition deadlines for the EU Medical Device Regulation (EU MDR), now set for 2027 and 2028. We explore what these extensions mean for manufacturers of legacy medical devices, emphasizing the critical actions that should have been completed by May and September 2024 to benefit from this extra time. The focus for 2025 shifts from new extension-specific filings to the continuous maintenance of an MDR-compliant Quality Management System, robust post-market surveillance, and up-to-date technical documentation, ensuring devices remain safe and that manufacturers are audit-ready. Key Questions: • What are the new EU MDR compliance deadlines for 2027 and 2028? • Did your company meet the critical May 26, 2024, application deadline? • Was a signed agreement with a Notified Body in place by September 26, 2024? • What does "maintaining compliance" truly mean for legacy devices in 2025? • Are there new EU MDR filings required in 2025 for the extension? • How does post-market surveillance change for legacy devices under these extensions? • What happens if significant changes are made to a legacy device? • What are the consequences of not meeting the 2024 prerequisites? • How can manufacturers ensure their QMS remains MDR-compliant throughout 2025? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    5 分
  • EU IVDR: Strengthening Your MedTech Supply Chain Controls

    EU IVDR: Strengthening Your MedTech Supply Chain Controls
    2025/05/29
    This episode delves into the critical supply chain requirements for Economic Operators under the EU's In Vitro Diagnostic Regulation (IVDR), referencing insights from April 14, 2025. We explore common pitfalls leading to Notified Body non-conformities, the specific obligations for manufacturers, importers, distributors, and authorized representatives, and strategies for ensuring your quality agreements and operational controls meet the stringent IVDR demands for enhanced traceability and patient safety in the EU market. Key Questions: • What are the four types of Economic Operators under EU IVDR and their core responsibilities? • Why are robust supply chain controls crucial for IVDR compliance and avoiding non-conformities? • Have the obligations for Economic Operators truly changed since May 2022, even for legacy devices? • What are the most common mistakes manufacturers make when defining Economic Operator roles and agreements? • How does EN ISO 13485 relate to controlling outsourced Economic Operator activities under IVDR? • What impact do new labeling, registration, and EUDAMED requirements have on IVD supply chains? • How can you ensure your quality agreements are up-to-date with IVDR Article 10-16 obligations? • Why is an existing ISO 13485 certificate not a guaranteed pass for supply chain audits? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    5 分
  • Unlocking Worldwide IVD Access with Europe's IVDR

    Unlocking Worldwide IVD Access with Europe's IVDR
    2025/05/28
    This episode explores how the European Union's stringent In Vitro Diagnostic Devices Regulation (IVDR) can strategically benefit IVD manufacturers seeking market access beyond the EU. We discuss leveraging IVDR CE Marking for easier entry into global markets, the role of harmonized quality management systems like ISO 13485, and the importance of a proactive global market access strategy in light of evolving international regulations, including the US FDA's QMSR effective February 2, 2026, and UK acceptance of CE marks until June 30, 2030. Key Questions: • How can the demanding EU IVDR actually simplify global market entry for IVD devices? • What is the significance of ISO 13485 in achieving broader international compliance? • How will the US FDA's QMSR, effective February 2, 2026, impact manufacturers with EU IVDR certification? • Which non-EU countries might recognize or streamline approvals based on an IVDR CE Mark? • Why is IVDR compliance becoming critical as legacy devices lose acceptance globally? • What are the key components of a successful global market access strategy for IVDs? • How can regulatory intelligence help IVD companies navigate complex international markets? • What opportunities does IVDR CE Marking create for accessing markets in Asia, Africa, the Middle East, and Latin America? • How long will the UK continue to recognize CE marking for market access (until June 30, 2030)? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    4 分
  • Leveraging Real-World Data: MHRA's Blueprint for Clinical Trials

    Leveraging Real-World Data: MHRA's Blueprint for Clinical Trials
    2025/05/27
    This episode delves into the UK's Medicines and Healthcare products Regulatory Agency (MHRA) guidance, updated 20 May 2025, on utilizing Real-World Data (RWD) in randomised controlled trials for regulatory decisions. We explore the scope, design considerations, safety monitoring, and regulatory acceptability of RWD-based trials, highlighting their potential to streamline drug development, particularly for label expansions and repurposing existing medicines. Key Questions: • What is the MHRA's latest stance on using Real-World Data in clinical trials as of May 2025? • How can RWD potentially reduce burdens and accelerate regulatory submissions for medicinal products? • What are the critical design elements for a successful RWD-based randomised controlled trial? • When might blinding be necessary in RWD studies, and why? • How does the MHRA view the evidentiary value of RWD trials compared to traditional RCTs? • What are "Type A" clinical trials, and how does this classification impact safety reporting requirements? • What are some of the most suitable scenarios for leveraging RWD in clinical investigations, such as drug repurposing? • Are there specific considerations for designing non-inferiority trials that use RWD sources? • How is the guidance expected to evolve concerning medical devices and RWD? • Where can sponsors obtain further advice from the MHRA on their specific RWD trial proposals? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30 + markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.
    続きを読む 一部表示
    5 分